{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Lung+Disease&page=7", "query": { "condition": "Advanced Lung Disease", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 2075, "total_pages": 208, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Lung+Disease&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Lung+Disease&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T18:37:30.596Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05208762", "title": "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Squamous Cell Carcinoma of the Head and Neck", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Neoplasms", "Gastric Cancer", "Endometrial Cancer", "Pancreatic Adenocarcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "PF-08046054", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 714, "start_date": "2022-10-25", "completion_date": "2029-01-04", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Irvine, California • Orange, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05208762" }, { "nct_id": "NCT07439094", "title": "A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "CKD-703", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chong Kun Dang Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 140, "start_date": "2026-04-16", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 1, "location_summary": "Ohio City, Ohio", "locations": [ { "city": "Ohio City", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07439094" }, { "nct_id": "NCT05687266", "title": "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Datopotamab deruxtecan", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1350, "start_date": "2022-12-29", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 52, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 45 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05687266" }, { "nct_id": "NCT04250545", "title": "Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leptomeningeal Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Telaglenastat Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-10-26", "completion_date": "2026-11-21", "has_results": true, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 7, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04250545" }, { "nct_id": "NCT00193453", "title": "Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2005-07", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2012-11-13", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 10, "location_summary": "Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 7 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00193453" }, { "nct_id": "NCT00435253", "title": "US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Emphysema" ], "interventions": [ { "name": "BLVR Treatment", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aeris Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 20, "start_date": "2007-02", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2011-10-24", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00435253" }, { "nct_id": "NCT04969315", "title": "TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Cancer", "Castrate Resistant Prostate Cancer", "Non Small Cell Lung Cancer", "Pleural Mesothelioma Malignant" ], "interventions": [ { "name": "TT-10", "type": "DRUG" }, { "name": "TT-4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Portage Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2023-06-23", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04969315" }, { "nct_id": "NCT02955290", "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "PD-L1 Positive", "Recurrent Head and Neck Squamous Cell Carcinoma", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma", "Advanced Squamous Non-Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2016-12-22", "completion_date": "2027-12-09", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 5, "location_summary": "Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "Roslyn", "state": "New York" }, { "city": "West Islip", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955290" }, { "nct_id": "NCT05655546", "title": "ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Immunodeficiency", "Immunosuppression", "HIV Infections", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Cancer", "Multiple Myeloma", "Transplant", "Age-Related Immunodeficiency" ], "interventions": [ { "name": "Access to Cue Health COVID-19 Remote testing and treatment for COVID-19", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Scripps Translational Science Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 2117, "start_date": "2022-12-22", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2025-08-08", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05655546" }, { "nct_id": "NCT07229313", "title": "A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advance Solid Tumors" ], "interventions": [ { "name": "KIVU-107", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kivu Bioscience Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2025-11-13", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-05T18:37:30.596Z", "location_count": 2, "location_summary": "Santa Monica, California • New Have, Connecticut", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Have", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07229313" } ] }